Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease

Crohn Disease Clinical Trial

Official title:

Oral Cannabidiol Capsule Usage as an Adjunct Therapy for Crohn's Disease: a Randomized, Placebo-controlled Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03467620
• Other study ID #: 2018-0529 Adm Withdrawn
• Status: Withdrawn
• Phase: Phase 2/Phase 3
• Start date: July 2018
• Est. completion date: July 2019

Study information

• Verified date: March 2020
• Source: University of Illinois at Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To date, few studies have assessed the efficacy and safety of Cannabinoids, compounds derived from the Cannabis plant, in patients with Crohn's disease. Our study seeks to pilot a randomized, placebo-controlled trial assessing the efficacy and safety of oral cannabinoids as an adjunct therapy in patients with Crohn's disease.

Description:

Crohn's disease is a type of inflammatory disease which can affect any portion of the gastrointestinal tract, from the mouth to the perianal area. Symptoms depend on location of the disease, however, many patients experience some aspect of recurrent abdominal pain, nausea, emesis, and unintentional weight loss. A common and challenging dilemma is how to manage patients who continue to have some degree of symptoms despite a common treatment regimen typically consisting of corticosteroids, thiopurines, methotrexate, or anti-TNF alpha therapies. With the recent wave of medicinal cannabis legalization in many states, many patients have begun using cannabis or commercially available cannabidiol-containing compounds as an adjunct therapy for their symptoms related to chronic inflammation and pain.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2019
• Est. primary completion date: July 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 or older

• English-speaking

• Ileal and/or ileocolonic involvement as demonstrated by most recent endoscopy

• Short CDAI score >150

• Have not received oral or intravenous steroids for >1 month, or with stable dose for >1 month if currently taking

• Stable dose of AZA for >1 month, if currently taking

• Stable dose of anti-TNF inhibitor for >1 month, if currently taking

Exclusion Criteria:

• Pregnant or intend to become pregnant in the next 6 months

• Major abdominal surgery within the past 3 months

Related Conditions & MeSH terms

• Cannabis
• Crohn Disease
• Inflammatory Bowel Diseases

Intervention

Drug:
• Cannabidiol
Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
• Placebo oral capsule
Administration of one oral placebo capsule daily for a duration of 12 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Illinois at Chicago

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CDAI (Clinical Disease Activity Index) score	A statistically significant decrease in CDAI score. The short CDAI score will be utilized for this study. This validated score consists of three subjective, patient-derived measures: (1) number of liquid or soft stools each day for 7 days (2) the sum of seven daily abdominal pain ratings (3) the sum of seven general well-being ratings. The calculation of CDAI score will be as follows: Short CDAI = 44 + (2 × the number of liquid or soft stools each day for 7 days) + [5 × the sum of seven daily abdominal pain ratings (0 = none, 1 = mild, 2 = moderate, 3 = severe)] + [7 × the sum of seven general well-being ratings (0 = generally well, 1 = slightly under par, 2 = poor, 3 = very poor, 4 = terrible). Outcome measures considered to be consistent with benefit from intervention includes either (1) disease remission (CDAI less than 150) or (2) CDAI score reduction of 60 points.	12 weeks
Primary	Fecal calprotectin	A statistically significant decrease in fecal calprotectin	12 weeks
Secondary	Morbidity	Rates of hospitalization and adverse events	12 weeks